The eczema market across the top seven global markets—comprising the United States, the EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan—was valued at USD 18.1 billion . According to a report by IMARC Group, this figure is projected to more than double, reaching USD 40.2 billion by 2035. The market is expected to grow at a compound annual growth rate (CAGR) of 7.57% between 2025 and 2035.
Eczema, or atopic dermatitis, is a chronic skin condition marked by inflammation, itching, dryness, and cracking. While it can affect people of all ages, it is most common in children. Some individuals outgrow the condition, but many continue to experience flare-ups throughout their lives.
The global increase in eczema cases is driven by various factors, including genetics, environmental changes, and lifestyle habits. Urban pollution, dietary changes, and rising exposure to allergens have all contributed to the condition’s growing prevalence. As a result, the demand for long-term, effective treatments is rising, creating new opportunities for pharmaceutical companies.
One major market trend in 2025 is the growing acceptance of prescription-based therapies. Traditionally, eczema has been managed with topical steroids and moisturizers, which offer only short-term relief and can have side effects with prolonged use. However, new treatments that target the immune system are now being adopted as first-line options.
In recent years, the market has shifted toward advanced treatments such as biologics and Janus kinase (JAK) inhibitors. These therapies are especially effective for moderate to severe eczema that does not respond well to topical treatments. Biologics like dupilumab have transformed eczema care by providing lasting symptom control with relatively few side effects. More biologic and oral treatment options are expected to become available in 2025.
Technology is also reshaping eczema management. Digital health tools help patients track symptoms, medication use, and environmental triggers. These platforms enable personalized treatment plans and improve adherence, especially among younger users. Teledermatology is expanding access to specialist care, particularly in rural or underserved areas.
Pediatric and adolescent care is becoming a greater focus in the eczema market. As the condition often begins in childhood, pharmaceutical companies are developing safer treatments suitable for young patients. At the same time, public awareness campaigns and school-based health initiatives are promoting early diagnosis and treatment.
In emerging markets, improved healthcare systems and higher health spending are making advanced eczema care more accessible. Governments and healthcare organizations are working together to include biologics in public health programs, reducing disparities between urban and rural care.
The IMARC report also provides in-depth analysis of current treatments on the market, as well as late-stage pipeline drugs expected to impact the industry in the near future.
Related Topics:
